Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Acadia Healthcare Company Inc (ACHC) vs Boston Scientific Corporation (BSX) Price & Performance

Acadia Healthcare Company IncTrade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

Acadia Healthcare Company Inc vs Boston Scientific Corporation — how do they compare? Acadia Healthcare Company Inc trades at $31.18 (market cap $2.96B), while Boston Scientific Corporation trades at $51 (market cap $71.46B). The key difference: Boston Scientific Corporation is far larger — about 24.1× Acadia Healthcare Company Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.

ACHCBSX
Market Cap
$2.96B$71.46B
Sector
HealthHealth
52-Week High
$35.61$108.14
52-Week Low
$11.68$42.63
Enterprise Value
$5.35B$83.55B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Acadia Healthcare Company Inc

ACHC trades at $31.53, up 2.64% today, with a neutral technical signal despite bullish moving averages. The company shows strong revenue growth with Q2 2026 earnings beating estimates, but faces profitability challenges with negative net income margins. Analyst consensus remains positive with 68% buy ratings and a $36 price target, though ongoing legal investigations create headwinds.

The outlook balances operational strength against financial risks. Revenue growth and facility expansion support upside potential, but negative profitability and legal uncertainties warrant caution. The stock offers 14% upside to consensus target if execution improves, but investors should monitor earnings sustainability and legal developments closely.

Boston Scientific Corporation

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Acadia Healthcare Company Inc

Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.

Read more on ACHC

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX